

Xeligekimab Biosimilar - Research Grade

Product Code: ICH5289

More Information

Species Reactivity: Human

Target: IL17A

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Xeligekimab Biosimilar - Research Grade

Antibodies against the same target: [Secukinumab Biosimilar - Research Grade \(ICH4033\)](#), [Ixekizumab Biosimilar - Research Grade \(ICH5165\)](#), [Afasevikumab Biosimilar - Research Grade \(ICH5330\)](#), [Bimekizumab Biosimilar - Research Grade \(ICH5403\)](#), [Gumokimab Biosimilar - Research Grade \(ICH5586\)](#), [Netakimab Biosimilar - Research Grade \(ICH5709\)](#), [Perakizumab Biosimilar - Research Grade \(ICH5769\)](#), [Roconkibart Biosimilar - Research Grade \(ICH5829\)](#), [Vunakizumab Biosimilar - Research Grade \(ICH5995\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q16552

Shipping Conditions: Blue ice

background: This is a research-grade biosimilar of xeligekimab (development code GR1501), supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not the clinical drug product and is not intended for human or veterinary use. Xeligekimab is a fully human IgG4-kappa monoclonal antibody engineered to bind and neutralize human interleukin-17A (IL-17A), the pro-inflammatory cytokine encoded at UniProt Q16552. The originator has been advanced clinically for IL-17-driven

inflammatory conditions, including moderate-to-severe plaque psoriasis and axial spondyloarthritis, where blockade of IL-17A signaling reduces downstream inflammatory mediator release. This biosimilar is built around that same target and binding activity, allowing investigators to study IL-17A engagement and neutralization in a controlled reagent format. It is produced to in-vivo research standards with low endotoxin and is available in bulk milligram-to-gram quantities, making it suitable as a reference or comparator molecule in binding, neutralization, and assay-development work. As with all ichor.bio biosimilars, it is offered as a functional research tool rather than a therapeutic, and results should be interpreted in that context. Interleukin-17A (IL-17A, UniProt Q16552) is a pro-inflammatory cytokine produced predominantly by Th17 cells, as well as gamma-delta T cells, innate lymphoid cells, and other immune populations. It signals as a disulfide-linked homodimer, and also as an IL-17A/IL-17F heterodimer, through a receptor complex comprising IL-17RA and IL-17RC. Engagement drives NF- κ B and MAPK signaling, inducing chemokines such as CXCL1, cytokines including IL-6, antimicrobial peptides, and matrix-remodeling factors. This axis contributes to mucosal and barrier defense against extracellular bacteria and fungi, but sustained or dysregulated IL-17A activity promotes tissue inflammation. IL-17A is a well-established driver in psoriasis, psoriatic arthritis, and axial spondyloarthritis, which is why antibodies that neutralize the cytokine and block its receptor interaction are of significant research and therapeutic interest.

Other names: IL-17, Cytotoxic T-lymphocyte-associated antigen 8, CTLA-8, Interleukin-17A

Specificity: Detects human IL17A

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks